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Abstract
The interplay between peritoneal mesothelial cells and
ovarian cancer cells is critical for the initiation and
peritoneal dissemination of, and ascites formation in,
ovarian cancer. The production of lysophosphatidic
acid (LPA) by both peritoneal mesothelial cells and
ovarian cancer cells has been shown to promote meta-
static phenotype in ovarian cancer. Herein, we report
that exogenous addition or ectopic overexpression of
the matricellular protein SPARC (secreted protein
acidic and rich in cysteine) significantly attenuated
LPA-induced proliferation, chemotaxis, and invasion
in both highly metastatic SKOV3 and less metastatic
OVCAR3 ovarian cancer cell lines. SPARC appears to
modulate these functions, at least in part, through the
regulation of LPA receptor levels and the attenuation
of extracellular signal–regulated kinase (ERK) 1/2 and
protein kinase B/AKT signaling. Moreover, our results
show that SPARC not only significantly inhibited both
basal and LPA-induced interleukin (IL) 6 production
in both cell lines but also attenuated IL-6–induced
mitogenic, chemotactic, and proinvasive effects, in
part, through significant suppression of ERK1/2 and,
to a lesser extent, of signal transducers and activators
of transcription 3 signaling pathways. Our results
strongly suggest that SPARC exerts a dual inhibitory
effect on LPA-induced mesothelial–ovarian cancer cell
crosstalk through the regulation of both LPA-induced
IL-6 production and function. Taken together, our find-
ings underscore the use of SPARC as a potential thera-
peutic candidate in peritoneal ovarian carcinomatosis.
Neoplasia (2007) 9, 23–35
Keywords: SPARC, LPA, IL-6, ovarian cancer, mesothelial cells.
Introduction
Epithelial ovarian cancer is the leading cause of death from
malignant gynecologic tumors. Currently, more than 75%
of ovarian cancers are diagnosed at International Federa-
tion of Gynecology and Obstetrics stages III and IV [1], with
solid tumor masses growing either as peritoneal implants
or as floating tumor cells within ascitic fluid. High mortality is
predominantly due to occult progression of tumors in the
peritoneal cavity—a condition known as peritoneal ovarian
carcinomatosis. The mesothelial lining of the peritoneal cavity,
as a host for tumor cells, provides the appropriate ‘‘soil’’ for the
shedding of ovarian cancer cells, which are ‘‘seeds.’’ Cancer
cells can induce changes in the surrounding microenvironment
that actively support tumor progression, creating the so-called
‘‘reactive tumor microenvironment.’’ In the context of ovarian
cancer, this reactive supporting microenvironment is composed
of the mesothelial lining of the peritoneal cavity, extracellular
matrix (ECM) components, inflammatory and immune cells,
and ascitic fluid exuded from hyperpermeable blood vessels.
Lysophosphatidic acid (LPA) has been shown to be an
essential microenvironmental factor in ovarian cancer. It is ele-
vated in the blood and ascites of patients with ovarian cancer
[2,3]. Several lines of evidence suggest that LPA signaling is
involved in the initiation, progression, andmetastasis of ovarian
cancer [4,5], and imparts a cytoprotective effect to ovarian
cancer cells exposed to cisplatin [6]. LPA also induces the pro-
duction of potent inflammatory cytokines, which further facili-
tate tumor survival and a more aggressive behavior of tumor
cells [7]. LPA is produced by a variety of cells, including meso-
thelial cells, macrophages, activated platelets, endothelial
cells, and ovarian cancer cells [8,9]. Recently, peritoneal me-
sothelial cells have been reported to constitutively produce
LPA, highlighting them as an important source not only of
elevated LPA levels found in ovarian cancer ascites but, more
importantly, of the initiation and maintenance of the pathogenic
cascade of peritoneal ovarian carcinomatosis through pre-
servation of a reactive microenvironment that is supportive of
tumor progression [10].
Interleukin (IL) 6 is a potent pleiotropic inflammatory cytokine
that mediates a plethora of physiological functions [11] and has
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been implicated in tumor growth, metastasis, and resistance
to chemotherapy in a variety of tumor cells [12]. Depending
on cell type, IL-6 is able to act through several classic protein
kinase cascades, such as mitogen-activated protein kinase
and phosphatidylinositol triphosphate kinase (PI-3K)/AKT
[13]. Moreover, the ability of IL-6 to directly activate signal
transducers and activators of transcription (STAT) 3 pro-
duces serious unintended consequences when examined
in the context of tumor progression [11,14,15]. Recently,
IL-6 was suggested to be an independent marker of health-
related quality of life in ovarian cancer patients. High levels
of IL-6 in the sera and ascitic fluid of ovarian cancer pa-
tients correlated with the psychosocial stress and depression
frequently encountered in ovarian cancer patients [16].
SPARC (secreted protein acidic and rich in cysteine), also
known as osteonectin and BM-40, is a matricellular glyco-
protein that mediates cell–matrix interactions. In addition to
its counteradhesive and antiproliferative functions, SPARC
modulates angiogenesis and regulates the production,
assembly, and organization of the ECM [17]. The role of
SPARC in tumorigenesis is complex due to its diverse
functions in a given microenvironment. We and others have
shown that SPARC functions as a tumor suppressor in
ovarian cancer [18,19]. However, information regarding the
effect of SPARC on the normalization of the reactive tumor
microenvironment, rendering it unfavorable for tumor growth,
is limited. Herein, we studied the role of SPARC in the
regulation of crosstalk between ovarian cancer cells and
peritoneal mesothelial cells. Particular emphasis was given
to the interaction of SPARC with LPA, the key player in the
initiation and maintenance of the reactive microenvironment
in ovarian cancer.
Materials and Methods
Antibodies and Reagents
SPARC from mouse parietal yolk sac was purchased
from Sigma (St. Louis, MO). Human and bovine osteonectin,
and mouse monoclonal anti–human osteonectin antibody
were purchased from Hematologic Technologies (Essex,
VT). 1-Oleoyl-LPA was purchased from Sigma. LPA was
dissolved in vehicle [phosphate-buffered saline (PBS) con-
taining 1% fatty acid– free bovine serum albumin (BSA);
Sigma]. The phospholipase inhibitor AACOCF3 was pur-
chased from Calbiochem (San Diego, CA). Recombinant
human IL-6 and human IL-6–neutralizing antibodies were
purchased form Peprotech (Rocky Hill, NJ). Human plasma
fibronectin (FN) was from BD Biosciences (Bedford, MA).
Hemacolor 3 stain was purchased from Fisher Scientific
(Fairlawn, NJ). Antibodies against AKT/PKB, extracellular
signal–regulated kinase (ERK) 2, STAT3, phospho-AKT/
PKBSer473, phospho-ERK1/2, and phospho-STAT3 were
purchased from Cell Signaling (Beverly, MA). Horseradish
peroxidase (HRP)–conjugated secondary antibodies were
from Jackson ImmunoResearch (West Grove, PA). All other
chemicals were of analytical grade and were purchased
from Sigma and Fisher Scientific.
Cell Culture
An immortalized human mesothelial cell line, Meso 301,
originally obtained from a premenopausal woman with endo-
metrial cancer and normal human ovarian surface epithelial
(HOSE) cells were isolated under a protocol approved by
the internal review board of the Brigham and Women’s
Hospital (Boston, MA). Both cell lines were immortalized with
HPVE6E7 and maintained in Medium 199/MCDB110 (1:
1 mixture) supplemented with 2 mM L-glutamine and 15%
fetal bovine serum (FBS; Atlanta Biologicals, Norcross, GA).
The ovarian cancer cell lines SKOV3 (originally isolated from
the ascitic fluid of a patient with recurrent platinum-resistant
ovarian cancer) and NIH:OVCAR3 were obtained from the
American Type Culture Collection (Manassas, VA) and
maintained in McCoy’s 5A and RPMI 1460 medium supple-
mented with 15% FBS, which was in turn supplemented
with 100 mU/ml penicillin and 100 mg/ml streptomycin. All
media and supplements were purchased from Sigma.
Generation of SPARC Adenovirus
The gene encoding a conserved sequence of murine and
human SPARC was isolated from murine aorta through re-
verse transcription–polymerase chain reaction (RT-PCR). In
brief, total RNA was extracted from frozen tissues using
TRIzol (Invitrogen, Carlsbad, CA). cDNA was synthesized
from oligo-dT primed total RNA (1 mg) using Superscript II
(Invitrogen). The 0.91-kb gene for SPARCwas amplified using
primers (accession no. BC004638; sense 5V-CACCATGAG-
GGCCTGGATCTTCTTTC-3V and antisense 5V-GATCACCA-
GATCCTTGTTGATG-3V) and subcloned into the adenoviral
shuttle vector pAdTrack (Stratagene, La Jolla, CA). Sub-
sequent clones were verified for integrity through bidirectional
DNA sequencing and protein expression. Replication-deficient
adenoviruses expressing either SPARC or green fluorescent
protein (GFP), under the control of the cytomegalovirus (CMV)
promoter, were generated using the pAdTrack-CMV vector
and AdEasy System (Stratagene). Viruses were amplified in
HEK293 cells, purified using CsCl2, titrated using a cytopathic
effect assay, and stored in PBS containing 5% sucrose/2 mM
MgCl2. SKOV3 cells were transducedwith SPARC and control
(GFP) adenoviruses at a multiplicity of infection of 15 to 25,
and SPARC production was confirmed in cell lysates and con-
ditioned media by Western blot analysis after 24 hours. The
levels and activities of SPARC secreted into the conditioned
medium of transduced ovarian cancer cell lines were found to
be within the range of concentrations of exogenous SPARC
used in the experiments described herein, as determined by
semiquantitative Western blot analysis and proliferation
assays, respectively.
Preparation of Mesothelial Cell Conditioned Medium
Subconfluent cultures of Meso 301 cells were washed
thrice with PBS and incubated with serum-free medium
(SFM) for 24 hours. Conditioned media were collected and
centrifuged to remove cell debris, and half of the conditioned
media were heated at 95jC for 5 minutes. Heated and
unheated conditioned media were then sterilized through
0.22-mm filters and stored at 80jC.
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Migration Assays
Migration of ovarian cancer cells was assayed in 24-well
plates and transwell inserts (8-mm pore-size polycarbonate
filters, Corning Costar; Fisher Scientific) as described pre-
viously [18]. The lower surface of the filter was coated with
FN at a concentration of 10 mg/ml. SKOV3 and OVCAR3
cells were starved overnight, and 1  105 cells in 100 ml were
added to the upper chamber. Migration assays were carried
out for 5 hours, at the end of which the contents of the top
chambers were aspirated. Cells attached to the upper sur-
face of the inserts were scraped with cotton swabs (Fisher
Scientific), and cells attached to the bottom surface of the
inserts were stained with Hemacolor 3 stain, as recom-
mended by the manufacturer. Cells were counted in six fields
per insert using an inverted microscope equipped with a DFC
320 digital camera (Leica Microsystems, Wetzlar, Germany;
original magnification, 200).
Mesothelial Cell Invasion
Peritoneal mesothelial cells were grown to confluent
monolayers in transwell inserts (8-mm pore-size poly-
carbonate filters). SKOV3 and OVCAR3 cells (1  105 cells
in 100 ml) were added to the upper chamber and allowed to
invade mesothelial monolayers for 72 hours. The contents of
the upper chambers were aspirated, cells attached to the
upper surface of the inserts were scraped, and cells at-
tached to the bottom surface were stained and counted as
described above.
RT-PCR
Total RNA was isolated from cultured cell lines using
TRIzol reagent (Invitrogen) according to the instructions of
the manufacturer. RNA was further purified with RNeasy
isolation kit (Qiagen, Valencia, CA). Total RNA (2 mg) was
reverse-transcribed in a 20-ml reaction system using an
Improm II RT enzyme kit (Promega, Madison, WI) as de-
scribed by the supplier. cDNAwas prepared from 2 mg of total
RNA with oligo-dT primers according to the cDNA synthe-
sis ImProm-II protocol (Promega). cDNA was amplified in a
20-ml reaction system containing 200 mM of each dNTP
(Promega) and 25 pmol of each primer, with the standard
buffer containing 1 U of Jumpstart Taq polymerase (Sigma)
and 1.5 mM MgCl2. Specific oligonucleotide primer pairs
used for LPA receptors were derived from a published report
[7] and were as follows: LPA1/Edg-2, 5V-CAAAATGAGGCCT-
TACGACGCCA-3 V and 5 V-TCCCATTCTGAAGT-
GCTGCGTTC; LPA2/Edg-4, 5V-GCGCGCGGATCCAC-
CATGGTCATCATGGGCCAGTGCT-3V and 5V-GCGC-
GGTCGACTCAGTCCTGTTGGTTGGGTTGA-3V; LPA3/
Edg-7, 5V-CTGATGTTTAACACAGGCCC-3V and 5V-GAC-
GTTGGTTTTCCTCTTGA-3V; and GAPDH, 5V-CACTG-
GCGTCTTCACCACCATG-3V and 5V-GCTTCACCACCT-
TCTTGATGTCA-3V (450 bp). Reaction conditions were as
follows: initial denaturation at 95jC for 4 minutes, followed
by 30 cycles (25 cycles for GAPDH ) of 95jC for 30 seconds,
56jC for 45 seconds, and 72jC for 1 minute, and a final
elongation at 72jC for 8minutes. PCRproducts were resolved
on 2% agarose gels containing ethidium bromide and were
visualized under UV light. Gel imaging, documentation, and
analysis were performed with a Kodak digital camera linked
to Kodak D 3.6 software (Fisher Scientific).
Nonradioactive Cell Proliferation Assay
CellTiter96 kit (Promega) was used according to the man-
ufacturer’s instructions. SKOV3 and OVCAR3 cells that were
serum-starved overnight were harvested by mild trypsiniza-
tion. Cells (1  105) were seeded in each well of a 96-well
plate in a complete growth medium and allowed to attach for
4 hours. Cells were then switched to a growth medium con-
taining 5% FBS, with the indicated concentrations of LPA,
in the presence of PBS vehicle or SPARC (10 mg/ml), which
was replenished every 24 hours. After 72 hours, 20 ml of MTS
was added to each well for an additional 3 hours. The number
of proliferating cells was determined colorimetrically by mea-
suring the absorbance at 590 nm (A590) of the dissolved
formazan product. All experiments were carried out in tripli-
cate, and the results were expressed as mean ± SEM.
Immunoblotting
Subconfluent monolayers of SKOV3 and OVCAR3 cells
were serum-starved for 20 hours and pretreated with SPARC
(20 mg/ml) for 2 hours. Cells were then stimulated as de-
scribed in figure legends and harvested in lysis buffer (20 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 50 mM NaF,
0.5% sodium deoxycholate, 1% NP-40, 1 mM Na3VO4, and
1 protease inhibitor cocktail mixture). Lysates were cleared
by centrifugation at 12,000g for 20 minutes at 4jC. Twenty-
five to 40 mg of cell lysates was resolved by 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred onto PVDF membranes (BioRad, Hercules, CA).
The membranes were incubated overnight with phospho-
specific antibodies against ERK1/2, AKT, and STAT3 at
4jC.Protein detectionwas carried out usingHRP-conjugated
anti-mouse or anti-rabbit secondary antibodies and a Super-
Signal West Dura Chemiluminescence kit (Pierce, Rock-
ford, IL). Membranes were then stripped (Restore Western
Blot Stripping Buffer; Pierce) and reprobed with antibodies
against total ERK2, AKT, and STAT3 to ensure equal pro-
tein loading.
Cytokine Antibody Array
Subconfluent serum-starved SKOV3 cells grown in
60-mm plates were pretreated with PBS (control) or SPARC
(20 mg/ml) for 2 hours before stimulation with LPA (50 mM) for
an additional 24-hour period. Conditioned media were then
collected, centrifuged to remove cell debris, and concen-
trated by 10-kDa cutoff centricons (Millipore, Billerica, MA).
Forty inflammatory cytokines were assayed using RayBio
Human Inflammation Antibody Array III (RayBiotech, Nor-
cross, GA). After exposing the membranes to blocking
buffer, they were incubated with the collected conditioned
medium from SKOV3 cells treated with LPA and/or SPARC
for 24 hours. Membranes were then processed to visualize
protein levels of various inflammatory cytokines according to
the manufacturer’s instructions.
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Measurement of IL-6 Production by Enzyme-Linked
Immunosorbent Assay (ELISA)
Culture supernatants were collected and used for the
determination of IL-6 concentration by ELISA using a human
IL-6 ELISA kit (RayBiotech) according to the manufacturer’s
instructions. Each measurement was performed in duplicate,
and average values were recorded as picograms permilliliter.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
version 3.1 for Windows (GraphPad Software, San Diego
CA). The significance of the results using different concen-
trations of LPA and IL-6 on ovarian cancer cell lines was
determined by one-way analysis of variance followed by
Newman-Keuls multiple comparison post hoc test. All other
statistical analyses were determined by Student’s t test.
Differences were considered significant at P < .05.
Results
Conditioned Medium from Meso 301 Induces Ovarian
Cancer Cell Migration
Previous studies have shown that the conditionedmedium
from primary human peritoneal mesothelial cells isolated
from a patient with ovarian cancer stimulated the migration
of ovarian cancer cells mainly through LPA in heat-resistant
fractions [10]. In agreement with these findings, the con-
ditioned medium from the immortalized cell line Meso 301,
which was isolated from an otherwise healthy peritoneum,
was shown to significantly (approximately nine-fold) increase
the chemotaxis of SKOV3 and OVCAR3 cells, compared to
the complete growth medium control (Figure 1, A and B).
Heat inactivation of biologically active peptides and proteins
in the conditioned medium resulted in f 40% decrease in
chemotactic activity compared to unheated controls. How-
ever, the chemotactic activity of the heat-sensitive fraction
was still significantly (approximately six-fold) higher than that
exerted by growth medium control. Pretreatment of ovarian
cancer cells with SPARC resulted in a significant (35–55%)
decrease in their chemotaxis toward heated or unheated
conditioned medium. Addition of the unheated and heated
conditioned media of Meso 301 to the upper chamber of
FN-coated transwell inserts resulted in increases in the
invasion of SKOV3 (3.8-fold and 2.3-fold) and OVCAR3
(2.3-fold and 1.5-fold), respectively, relative to medium con-
trols (Figure 1, C and D). SPARC treatment of SKOV3 and
OVCAR3 cells decreased conditioned medium–induced in-
vasion by asmuch as 40%and 30%, respectively. These data
demonstrate that SPARC significantly inhibits the chemo-
tactic and chemokinetic effects of both heat-sensitive and
heat-resistant fractions of mesothelial conditioned medium.
The inhibitory effect of SPARC was observed only when it
was added to ovarian cancer cells in the upper chamber of
the inserts. When added to the bottom chamber with either
the conditioned medium of Meso 301 or medium controls,
SPARC had no effect on chemotactic activity, suggesting that
it exerts its action on ovarian cancer cells rather than neu-
tralizing the chemotactic activity of the conditioned medium.
Recently, it has been shown that the biologic activity of
the heat-resistant fraction of mesothelial cell conditioned
medium is due to the constitutive production of LPA by the
action of phospholipases, mainly phospholipase A2 (PLA2)
[10]. Both cytosolic Ca2+-dependent PLA2 (cPLA2) and Ca
2+-
independent PLA2 (iPLA2) have been implicated in LPA pro-
duction by peritoneal mesothelial cells and/or LPA-induced
cell migration of ovarian cancer cells [10,20,21]. To determine
whether the activity of the heat-resistant fraction of Meso-
CM is due to LPA production, we included AACOCF3 (an
iPLA2 and cPLA2 inhibitor; 25 mM) during the generation of
the conditioned medium from Meso 301 cells (AACOCF3-
CM) to inhibit LPA production. Heated AACOCF3-CM sig-
nificantly reduced the migration and invasion of ovarian
cancer cells (by f 50–75%) compared to heated Meso-
CM controls (Figure 1, E–H ). The observed inhibitory effect
of AACOCF3 on SKOV3 and OVCAR3 migration and inva-
sion was concentration-dependent (data not shown), was
fully rescued by the addition of LPA (50 mM) to heated
AACOCF3-CM, and was not due to toxicity or reduced cell
viability (as determined by LIVE/DEAD viability/cytotoxicity
kit; Invitrogen data not shown). These results suggest
that the chemotactic and promigratory effects of the heat-
resistant fraction of Meso-CM on ovarian cancer cells were,
for the most part, due to PLA2-induced LPA production/
secretion in the conditioned medium. This production of
LPA from Meso 301 cells appeared to be constitutive be-
cause the conditioned medium was collected from cells in
SFM and in the absence of any stimuli.
SPARC Inhibits LPA-Induced Ovarian Cancer Cell
Migration and Invasion
Our finding that SPARC inhibits SKOV3 and OVCAR3
chemotaxis and FN invasion induced by heated Meso-CM
prompted us to test whether LPA-induced migration can
also be inhibited by SPARC. In agreement with earlier reports
[4], we found that the chemotactic effect of LPA (10–50 mM)
on SKOV3 and OVCAR3 cell lines was concentration-
dependent and resulted in up to 5.8-fold and 6-fold in-
creases inmigrating cells, compared to unstimulated controls
(Figure 2, A and C, respectively). SPARC significantly
inhibited the migration of SKOV3 and OVCAR3 cells toward
both the control medium (f 45% andf 70%, respectively)
and tested concentrations of LPA (up to 40%). LPA-induced
FN invasion by SKOV3 and OVCAR3 cells was also shown
to be concentration-dependent and resulted in 1.8-fold to
3-fold increases in FN invasion by SKOV3, and to 1.4-fold to
1.9-fold increases in FN invasion by OVCAR3 (Figure 2, B
and D). SPARC significantly inhibited control medium–
induced (by f 50–70%) and LPA-induced (25–40%) inva-
sion of FN by SKOV3 and OVCAR3 cell lines.
Adenoviral Transduction of SPARC Attenuates Ovarian
Cancer Cell Migration and Mesothelial Cell Invasion
SKOV3 and OVCAR3 cells neither express nor secrete
SPARC due to hypermethylation of the SPARC promoter
(Motamed et al., unpublished data). Conversely, Meso 301
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cells express and secrete SPARC into their conditioned
medium. We have recently reported that SPARC inhibits
ovarian cancer cell migration and ECM invasion [18]. There-
fore, we hypothesized whether restoring SPARC expression
by adenovirus gene transfer would attenuate the promigra-
tory effects of LPA on SKOV3 and OVCAR3 cells. Interest-
ingly, we found that ovarian cancer cells transduced with
GFP-SPARC adenovirus exhibited significantly (f 40%)
reduced migration toward the control medium, relative to
cells transduced with GFP alone (Figure 3, A and B). Al-
though LPA-induced migration was concentration-dependent
for both cell lines, cells transduced with GFP-SPARC ex-
hibited significant diminution in chemotaxis toward LPA
(f 40–60%) and heated and unheated Meso-CM (f 50%),
compared to controls. In all experimental conditions, OVCAR3
cells exhibited less migration than did SKOV3 cells. In agree-
ment with these findings, LPA was shown to induce the
FN invasion of both cell lines in a concentration-dependent
manner (Figure 3, C and D). SKOV3-GFP-SPARC exhibited
significant (f 40–60%) attenuation in FN invasion stimulated
by LPA or Meso-CM, compared to SKOV3-GFP controls
(Figure 3C). Similarly, OVCAR3-GFP-SPARC exhibited sig-
nificant attenuation in FN invasion stimulated by LPA or
Meso-CM, compared to OVCAR3-GFP controls (Figure 3D).
Figure 1. The conditioned medium from Meso 301 induces ovarian cancer cell motility through LPA. Subconfluent Meso 301 cells were allowed to condition in SFM
for 24 hours, and the collected conditioned medium (heated or not) was used as a chemoattractant (600 l in the bottom chambers of transwell inserts) for SKOV3
(A) and OVCAR3 (B) (1  105 cells/100 l of SFM–0.4% BSA in the upper chamber) in the presence or in the absence of SPARC (10 g/ml). Results are
expressed as the mean ± SEM of the fold change in cell migration induced by a complete medium in the bottom chamber as controls. FN invasion by SKOV3 (C)
and OVCAR3 (D) cells was tested in response to the conditioned medium of Meso 301 (heated or not) added with the cells to the upper chamber of transwell
inserts, in the presence or in the absence of SPARC (10 g/ml). LPA production by Meso 301 was inhibited by PLA2 inhibitor (AACOCF3). The conditioned medium
of Meso 301 serum-starved for 24 hours was collected in the absence (control conditioned medium) or in the presence of AACOCF3 (25 M) added at serum
starvation (AACOCF3-CM) or after the conditioned medium had been generated (conditioned medium + AACOCF3). All collected conditioned media were heat-
inactivated and added to the bottom chamber of transwell inserts, and the chemotactic activity of SKOV3 (E) and OVCAR3 (F) was tested in the aforementioned
conditioned medium and after replenishment with LPA (50 M; AACOCF3-CM + LPA). Results are expressed as the mean ± SEM of the fold change of the
chemotactic activity of heated conditioned medium under experimental conditions, compared to the conditioned medium (control conditioned medium) of Meso 301
heated for 24 hours. The effect of the abovementioned conditioned medium on FN invasion by SKOV3 (G) and OVCAR3 (H) was tested when they were added with
the cells to the top chambers of the inserts, whereas the bottom chambers contained a complete growth medium. Results are expressed as the mean ± SEM of the
fold change of the invasive activity of SKOV3 and OVCAR3 induced by different experimental conditions, relative to that induced by the conditioned medium
(control conditioned medium) of Meso 301 heated for 24 hours. Data summarized are representative of an experiment performed in triplicate and repeated thrice
with similar results. *P < .05, compared to unheated Meso-CM. **P < .05, compared to heated Meso-CM. #P < .05, compared to heated Meso-CM. bP < .05,
compared to AACOCF3-CM.
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Using a coculture system, LPA (50 mM) significantly (up to
two-fold) stimulated the invasion of Meso 301 monolayers by
SKOV3 and OVCAR3 cells in 72 hours (Figure 3, E and F ).
Exogenous addition (10 mg/ml) or overexpression of SPARC
significantly (up to f 45%) inhibited both basal and LPA-
stimulated invasions of Meso 301 by ovarian cancer cell lines
in thismodel system. To account for the knownantiproliferative
effect of SPARC on SKOV3 cells in this two-cell coculture
system, the number of viable ovarian cancer cells was deter-
mined in parallel studies by counting GFP-expressing cells in
the top chamber, attached to or invading through the meso-
thelial monolayer, and cells attached to the bottom surface of
the filter. These numbers were compared and corrected
according to the doubling time of SKOV3-GFP and SKOV3-
GFP-SPARC (21.5 and 34.9 hours, respectively) and that
of OVCAR3-GFP and OVCAR3-GFP-SPARC (39.7 and
50.8 hours, respectively). However, these parallel studies did
not reveal a significant difference in the total viable number of
the cell populations tested, suggesting that SPARC over-
expression in this two-cell coculture system did not result in
significant inhibition of SKOV3 cell proliferation. A plausible
explanation that can account for this observation is the con-
stitutive production of high levels of LPA and IL-6 by meso-
thelial cells, as well as the synergistic production of IL-6 (and
other mitogenic/prosurvival factors) from both ovarian cancer
cells and mesothelial cells in this model system.
SPARC Diminishes LPA-Induced Proliferation and Survival
Signaling in Ovarian Cancer Cells
High levels of LPA (up to 80 mM) have been reported in the
ascitic fluid of ovarian cancer patients [8,22–25]. At these
concentrations, LPA plays a critical role in the stimulation
of both anchorage-dependent proliferation and anchorage-
independent proliferation of ovarian cancer cells, prevention
of apoptosis and anoikis, and stimulation of the production
of mitogenic and prosurvival factors, including LPA it-
self [26,27]. We have previously reported the inhibition of
serum-induced ovarian cancer cell proliferation and survival
Figure 2. SPARC antagonizes LPA-induced ovarian cancer cell chemotaxis and invasion. LPA (10–50 M in SFM, added to the bottom chamber of transwell
inserts) stimulated the migration of SKOV3 (A) and OVCAR3 (C) cells in a concentration-dependent manner. SPARC (10 g/ml) added with SKOV3 and OVCAR3
cells to the top chamber of the inserts inhibited LPA-induced migration. Results are expressed as the mean ± SEM of the fold change in migrated cells under
experimental conditions, compared to controls attracted by a complete growth medium placed in the bottom chamber (assigned a value of 1). LPA (10–50 M in
SFM) added to SKOV3 (B) and OVCAR3 (D) cells in the top chamber stimulated the invasion of FN-coated inserts and the migration of both cell lines toward a
complete growth medium in the bottom chamber. The effect of LPA on FN invasion was significantly inhibited by SPARC. Results are expressed as the mean ±
SEM of the fold change in invading cells under experimental conditions, compared to control cells exposed to 0.4% BSA in SFM (assigned a value of 1).
Represented are the results of an experiment performed in triplicate and repeated thrice with similar results. *P < .05, compared to unstimulated control. **P < .05,
compared to control or LPA stimulation.
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signaling by SPARC [18,19,28]. LPA stimulation resulted in a
concentration-dependent increase in the proliferation of
SKOV3 (more than eight-fold; Figure 4A) and OVCAR3
(more than four-fold; Figure 4B), compared to unstimulated
controls. SPARC (10 mg/ml) significantly inhibited (f 15–
20%) the proliferation of SKOV3 at low (5–10 mM), but not
high (20–50 mM), concentrations of LPA. However, the
inhibitory effect of SPARC on LPA-induced OVCAR3 pro-
liferation was significant (20–45%) at all tested concentra-
tions of LPA. We next determined the effect of SPARC on
LPA-mediated survival signaling pathways and found that
SPARC significantly inhibited LPA-induced ERK1/2 and AKT
phosphorylation in SKOV3 cells in as early as 5 minutes—an
effect that was sustained for up to 60 min (Figure 4C). A
similar inhibitory effect of SPARC on LPA-induced ERK1/2
and AKT phosphorylation was also observed in OVCAR3
cells (Figure 4D).
Regulation of LPA Receptor Expression in SKOV3 Cells
By SPARC
It has been suggested that the net effect of LPA on ovarian
cancer cells depends on the outcome of activation of its
different receptors [26]. We determined the effect of SPARC
on LPA receptor expression by semiquantitative RT-PCR.
Interestingly, we found that SPARC upregulated LPA1/
Edg2 and downregulated LPA2/Edg4 basal expression levels
(Figure 5, A and B), consistent with the role of SPARC as a
negative regulator of ovarian cancer. The significance of
SPARC augmenting the expression levels of LPA3/Edg7 is
not known and is yet to be elucidated. Normal HOSE cells,
which are known to express only LPA1/Edg2, were used as
controls. These findings suggest that SPARC mediates its
negative regulatory role on LPA signaling in SKOV3, at least
in part, through alterations in the expression of LPA recep-
tor repertoire.
SPARC Suppresses Secretion of IL-6 in Ovarian
Cancer Cells
LPA has been shown to induce inflammatory cytokines
that further augment peritoneal ovarian carcinomatosis [27].
IL-6 is a secreted multifunctional glycoprotein that was
found to be present at high levels in the serum and ascites
of ovarian cancer patients [29,30]. LPA enhances IL-6 ex-
pression and secretion by ovarian cancer cells, but not in
normal ovarian epithelial cells. This selective induction was
attributed to LPA2/Edg4-LPA3/Edg7 receptors in cancer cells
[7]. To determine whether SPARC affects LPA-induced IL-6
production in SKOV3, we used a growth factor/cytokine
Figure 3. Restoration of SPARC expression in ovarian cancer cells antagonizes LPA-induced and Meso-CM– induced chemotaxis and invasion. SKOV3 and
OVCAR3 cells were transduced (> 90% transduction efficiency) with GFP or GFP-SPARC adenoviruses and allowed to recover for 24 hours in a complete growth
medium. LPA (10–50 M)– induced and Meso-CM– induced chemotaxis of SKOV3 (A) and OVCAR3 (B) were tested as described in the legend to Figure 1.
*P < .05, compared to unstimulated control cells attracted by a complete growth medium in the bottom chamber. #P < .05, compared to matched LPA or Meso-CM
stimulation. LPA-induced and Meso-CM– induced FN invasions by SKOV3 (C) and OVCAR3 (D) were also tested as described earlier. *P < .05, compared to
unstimulated control cells in SFM containing 0.04% BSA added to the top chamber of the transwell inserts. #P < .05, compared to matched LPA or Meso-CM
stimulations. Results are expressed as the mean ± SEM of a representative of three independent experiments. In a two-cell coculture model described in the
Materials and Methods section, LPA (50 M)–stimulated invasion of Meso 301 monolayers by untransduced (WT) SKOV3 (E) and OVCAR3 (F) cells was
significantly inhibited in the presence of exogenous SPARC (10 g/ml), as well as by SKOV3 and OVCAR3 cells transduced with an adenovirus overexpressing
SPARC. *P < .05, compared to unstimulated WT or GFP-transduced (GFP) cells. **P < .05, compared to LPA-stimulated WT or GFP-transduced cells. #P < .05,
compared to unstimulated GFP-SPARC– transduced (GFP-SPARC) cells. Results are expressed as the mean ± SEM of a representative of three independent
experiments performed in quadruplicate.
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Figure 4. Effect of SPARC on LPA-induced proliferation and survival signaling in ovarian cancer cells. Cell proliferation of SKOV3 (A) and OVCAR3 (B) cells in
response to indicated concentrations of LPA, in the presence (open bars) and in the absence (closed bars) of SPARC, was assessed by measuring the released
formazan at A590. Results are expressed as the mean ± SEM of the fold increase in proliferation relative to unstimulated control cells (assigned a value of 1). *P <
.05, LPA-stimulated cells compared to control cells and between different concentrations of LPA. **P < .05, SPARC-treated versus matched unstimulated control or
LPA-stimulated cells. Represented are the results of one experiment performed in quadruplicate that was representative of two independent experiments. SKOV3
(C) and OVCAR3 (D) cells starved overnight were pretreated with 20 g/ml SPARC in SFM for 2 hours, followed by stimulation with 50 M LPA for indicated time
points. Western blot analysis of phosphorylated and total ERK1/2 and AKT was performed as described in the Materials and Methods section. Blots represent the
results of three independent experiments. NS = not stimulated; SP = SPARC-treated.
Figure 5. Effect of SPARC on LPA receptor expression in SKOV3 cells. SKOV3 cells serum-starved overnight were treated with PBS (control) or SPARC (10 g/
ml) for 6 hours. The expression of LPA receptors Edg2/LPA1 and Edg4/LPA2 and Edg7/LPA3 was determined by semiquantitative RT-PCR. PCR products of LPA
receptors and GAPDH were run on 2% agarose gels (A). Expression levels were normalized to that of the housekeeping gene GAPDH and were represented as
a bar graph (B). HOSE cells serum-starved overnight were used as controls for LPA receptor expression. Results shown are from one experiment that was
representative of three independent experiments. *P < .05, compared to corresponding control SKOV3 cells.
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array to identify factors secreted by SKOV3 after LPA stim-
ulation in the presence or in the absence of SPARC. Array
spots were analyzed, and the intensity of each spot was com-
pared with respective spots in the control array (Figure 6A).
Our data showed that LPA significantly increased the pro-
duction of IL-6 by SKOV3 cells, and SPARC treatment
significantly decreased both basal and LPA-stimulated IL-6
production. Results from our quantitative IL-6 ELISA con-
firmed that SPARC was able to significantly inhibit basal
(f 68%) and LPA-induced IL-6 production in SKOV3 and
OVCAR3 cell lines (Figure 6B). In addition to significant
increases in IL-6 levels, LPA stimulation also upregulated
the following inflammatory cytokines and growth factors:
granulocyte–macrophage colony-stimulating factor, IL-6
soluble receptor (IL-6sR), IL-8, interferon g-inducible protein
10 (IP10), monocyte chemoattractant protein (MCP) 1,
macrophage colony-stimulating factor, transforming growth
factor b1, and platelet-derived growth factor (PDGF) BB
relative to unstimulated SKOV3 controls. SPARC treatment
of SKOV3 cells for 24 hours significantly inhibited the basal
levels of all aforementioned cytokines. SPARC pretreatment
of SKOV3 cells decreased levels of LPA-induced IL-1a,
IL-6sR, IP10,MCP-1, andPDGF-BBwith no noticeable effect
on the levels of other upregulated cytokines. These results
indicate that SPARC strongly inhibits both basal and LPA-
induced production of IL-6 by ovarian carcinoma cells and,
to a lesser extent, the levels of other proinflammatory cyto-
kines and growth factors that may in turn augment the
functions of IL-6 and/or contribute to the production of LPA
and IL-6 by other cells in the microenvironment of peritoneal
ovarian carcinomatosis.
Coculture of Meso 301 and Ovarian Cancer Cells Results
in a Synergistic Increase in IL-6 Levels
In agreement with earlier reports suggesting that peri-
toneal mesothelial cells may be a prominent source of IL-6
in ovarian cancer-related ascites [31,32], we found that
steady-state secretion of IL-6 byMeso 301was 10-fold higher
than both SKOV3 and OVCAR3 cell lines (Figure 7). How-
ever, addition of the same number of ovarian cancer cells to
confluent monolayers of Meso 301 in a coculture system re-
sulted in synergistic augmentation of IL-6 production (32-fold
and 3.5-fold higher than either cell lines and Meso 301,
respectively). Restoring SPARC expression in ovarian can-
cer cells by adenoviral gene transfer reduced IL-6 produc-
tion from Meso ovarian cancer cell cocultures relative to
Figure 6. SPARC inhibits basal and LPA-induced IL-6 secretions from ovarian cancer cells. A human inflammation cytokine protein array was used to detect
differences in the protein levels of inflammation-related factors secreted into the conditioned medium of serum-starved SKOV3 cells pretreated with PBS (control)
or SPARC (10 g/ml) for 2 hours and stimulated with LPA (50 M) for 24 hours (A; left panel). A higher magnification of duplicate spots from the cytokine array
depicting protein levels of selected inflammation-related factors that were significantly upregulated by LPA and attenuated by SPARC (A; right panel). (1) IL-6. (2)
IL-6sR. (3) MCP-1. Quantification of IL-6 secretion by ELISA in conditioned media of SKOV3 (B; left panel) and OVCAR3 cells (B; right panel) in the presence or in
the absence of LPA and SPARC. *P < .05, compared to unstimulated control cells. **P < .01, compared to LPA-stimulated cells. Results shown are from one
experiment that was representative of three independent experiments.
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untransduced (by f 28%) or GFP-transduced cells (by
f 24%). To account for the antiproliferative effect of SPARC
on SKOV3 and OVCAR3 cells in this two-cell coculture
system, we first determined whether proliferation plays a
significant role in the invasion of mesothelial monolayers by
these cancer cell lines. Results of our pilot studies performed
in the presence or in the absence of the proliferation inhibitor
mitomycin C (used at a concentration range that resulted in a
50–75% inhibition of LPA-induced proliferation of either cell
line) did not show a statistically significant difference in the
number of invading tumor cells (data not shown). Hence, we
concluded that proliferation does not play a significant role
in this two-cell coculture invasion assay. To further confirm
these results, the number of viable ovarian cancer cells
(transduced with GFP alone or GFP-SPARC) was quantified
in parallel studies by countingGFP-expressing cells in the top
chamber, attached to or invading through the mesothelial
monolayer, as well as cells attached to the bottom surface of
the filter after 72 hours. In agreement with our mitomycin C
experiments, these parallel studies did not reveal a signifi-
cant difference in the total number of viable cell populations
tested, suggesting that SPARC overexpression in this two-
cell coculture system did not result in significant inhibition
of SKOV3 cell proliferation (data not shown). A plausible
explanation that can account for this observation is the con-
stitutive production of high levels of LPA and IL-6 by meso-
thelial cells, as well as the synergistic production of IL-6
(and other mitogenic prosurvival factors) from both ovarian
cancer cells and mesothelial cells in this model system. It is
also noteworthy that IL-6 production by SKOV3 cells (trans-
duced or not) was significantly higher than that of OVCAR3
cells either alone or in coculture with Meso 301 cells. Inter-
estingly, ectopic expression or exogenous addition of SPARC
had no significant effect on the proliferation, survival, or
IL-6 production of Meso 301 (data not shown).
Effect of SPARC on IL-6–Mediated Proliferation
and Survival Signaling of Ovarian Cancer
Previous studies have shown that IL-6 promotes tumor
cell proliferation and metastasis of ovarian cancer cell lines
[14,33], and exerts a potent proangiogenic effect that further
supports progression of the disease [34]. These effects of
IL-6 have been shown to be mediated through the activation
of downstream signaling molecules, of which STAT3 and
ERK1/2 are well characterized [7,14,27,34]. Similar to our
reported results with LPA (Figure 4), the effect of IL-6 on
SKOV3 and OVCAR3 proliferation was concentration-
dependent. SPARC (10 mg/ml) significantly inhibited the
proliferation induced by tested concentrations of IL-6 (5–
50 ng/ml; Figure 8, A and B). Analysis of the regulation of
IL-6– induced signaling by SPARC revealed inhibition of
ERK1/2 and STAT3 activation (Figure 8B). Because cultured
peritoneal mesothelial cells reportedly produce high levels
of IL-6, we also tested the effect of heated Meso-CM on
ERK1/2 and STAT3 phosphorylation. As expected, heated
Meso-CM strongly activated both ERK1/2 and STAT3 in
SKOV3 cells as early as 5 min, and this effect was attributed
to heat-resistant bioactive lipids, mainly LPA. Augmented
activation of ERK1/2 and STAT3 was noticed when IL-6
was replenished in heated Meso-CM. SPARC was able to
significantly suppress ERK1/2 activation but had a less
pronounced inhibitory effect on STAT3 activation (Figure 8C).
Effect of SPARC on IL-6–Induced Chemotaxis
and Invasion of Ovarian Cancer Cells
It has been reported that IL-6 stimulates ovarian cancer
cell migration and that higher levels of IL-6 correlated with
larger tumors, faster progression, relapses, and an overall
poor prognosis [16,31,33]. We studied the effect of SPARC
on IL-6– induced chemotaxis and FN invasion by SKOV3 and
OVCAR3 cells. Our results revealed that SPARC significantly
Figure 7. Effect of ovarian cancer –mesothelial cell coculture on IL-6 production. SKOV3 and OVCAR3 cells (WT) were transduced with GFP or GFP-SPARC in a
complete growth medium and allowed to recover for 24 hours. After trypsinization, 1  106 cells in SFM were added to confluent monolayers of the Meso 301 cell
line in 60-mm plates for an additional 24 hours. Conditioned media were collected, and IL-6 levels were determined by ELISA. *P < .01, between either SKOV3 or
OVCAR3 and Meso 301. *#P < .01, between cocultured Meso and untransduced (WT) or GFP-transduced SKOV3 or OVCAR3, compared to either cell line alone.
**P < .05, compared to WT or GFP-transduced cells. ***P < .05, between SKOV3 and OVCAR3 under all experimental conditions. Results shown are from one
experiment that was representative of three independent experiments.
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inhibited the concentration-dependent chemotactic effect of
IL-6 (10–50 ng/ml) on SKOV3 cells by 22% to 38%, and on
OVCAR3 cells by 40% to 70%, respectively, compared to the
inhibitory effect (up tof 58%) of IL-6–neutralizing antibody
(Figure 9, A and B). The inhibitory effect of SPARC on IL-6–
induced FN invasion of SKOV3 was only significant (f 18%)
at IL-6 concentrations of up to 10 ng/ml. Higher concentra-
tions of IL-6 (50 ng/ml) stimulated FN invasion by > 60%
relative to unstimulated controls and were significantly
(>38%) inhibited by the IL-6–neutralizing antibody but not
by SPARC (Figure 9C). In contrast, the inhibitory effect of
SPARC on IL-6– induced FN invasion of OVCAR3 was
significant (30–50%) at all tested concentrations of IL-6
and was comparable to the effect of the IL-6–neutralizing
antibody. These results implicate that the inhibitory role of
SPARC on IL-6– induced chemotaxis and invasion was more
pronounced in less invasive OVCAR3 cells compared to
highly metastatic SKOV3 cells.
Discussion
The importance of the reactive tumor microenvironment is
becoming increasingly appreciated. A decade ago, LPA was
identified as an ‘‘ovarian cancer–activating factor,’’ and high
levels of LPA in the ascitic fluid and serum of patients have
been correlated with poor prognosis of the disease [22–24].
In addition to the crucial paracrine effects of LPA on the
initiation and maintenance of the reactive tumor micro-
environment required for tumor progression, a positive auto-
crine feedback loop between peritoneal mesothelial cells and
ovarian cancer cells has been reported [10,35]. Herein, we
have identified a novel function of the matricellular protein
SPARC in blocking the tumor-promoting effect of LPA at
multiple levels. The most pronounced effect of SPARC was
found to be its inhibition of the chemotactic and proinvasive
effects of both LPA and peritoneal mesothelial cell condi-
tioned medium on ovarian cancer cells. This effect was
observed not only with SPARCadded exogenously to ovarian
cancer cells but also when the expression of SPARC was
rescued ectopically in these cells by adenoviral transduction.
These results are in agreement with our recent findings on
the counteradhesive effects of SPARCand its inhibitory effect
on survival signaling in ovarian cancer cell lines, in response
to serum and epidermal growth factor stimulation [18] (Said
et al., unpublished observations).
Pleiotropic biologic effects of LPA are mediated through
its interaction with cognate G protein–coupled receptors,
namely, LPA1/Edg 2, LPA2/Edge4, and LPA3/Edg7. The ex-
pression of LPA2/Edg 4 and LPA3/Edge7, which are not ex-
pressed in normal ovarian epithelial cells, is upregulated in
ovarian cancer cells and has been correlated with deleterious
effects of the disease. However, LPA1/Edg2 has been shown
to be a negative regulator of ovarian cancer progression
[26,36]. Our data suggest that the effect of SPARC on the
abrogation of the mitogenic, migratory, and prosurvival ef-
fects of LPA may be mediated, at least in part, through per-
turbation of the expression of LPA1/Edg2 and LPA2/Edg4
receptors, the balance of which was reported to determine
the net effect of LPA on ovarian cancer [26]. LPA is known
to induce proinflammatory cytokine production in different
Figure 8. Effect of SPARC on IL-6– induced proliferation and survival signaling pathways in ovarian cancer cells. Proliferation of SKOV3 (A) and OVCAR3 (B) cells
in response to indicated concentrations of IL-6, in the presence of PBS (Control) or SPARC (20 g/ml), was determined by MTS assay, as described previously.
Results are expressed as the fold change of the proliferation of IL-6–stimulated SKOV3 and OVCAR3 cells relative to the proliferation of PBS-stimulated (control)
cells (assigned a value of 1). *P < .05, from controls. **P < .05, from matched control or LPA-stimulated cells. SKOV3 cells serum-starved overnight were
pretreated with PBS (control) or SPARC (20 g/ml) for 2 hours, followed by stimulation with IL-6 (50 ng/ml), heat-inactivated Meso-CM, or heat-inactivated Meso-
CM plus IL-6 (50 ng/ml) for 5 minutes (C). The expression levels of phosphorylated and total ERK and STAT3 were determined by Western blot analysis, as
described previously. Results shown are from one experiment that was representative of three independent experiments.
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tumors, with IL-6 as one of the main cytokines implicated in
tumor survival, migration and angiogenesis [7,15,27,34,37].
LPA-induced upregulation of IL-6 in SKOV3 cell line has been
shown to be mediated through the activation of the Gi/PI-3K/
AKT pathway [7]. Therefore, our finding that SPARC exerts a
potent inhibitory effect on both basal and LPA-stimulated
proinflammatory cytokine production not only from SKOV3
cells but also from OVCAR3 cells strongly suggests that
these effects of SPARC are mediated through perturbation
of the balance between LPA receptor expression and inhibi-
tion of LPA-induced AKTactivation.
The high levels of IL-6 detected in the ascitic fluid of
ovarian cancer patients have been correlated with poor
prognosis and, until recently, the source of these high levels
had remained unidentified. The high basal levels of IL-6 in the
peritoneal mesothelial cell conditioned medium reported
herein and in other studies [31,32] can be correlated with
the constitutive production of biologically active LPA from
mesothelial cells [10], augmenting the chemotactic and
proadhesive effects of LPA on tumor cells. As shown in this
study, a pronounced synergistic increase in IL-6 secretion
occurs on mesothelial–tumor cell contact, further maintain-
ing the vicious cycle of disease cascade. Interestingly, rescue
of SPARC expression in ovarian cancer cells significantly
attenuated this dramatic increase in IL-6 secretion, albeit not
to that of basal levels produced by either ovarian cancer cells
or mesothelial cells. In addition to the pronounced inhibitory
effect of SPARC on IL-6 production by ovarian cancer cells,
SPARC had a negative regulatory role on levels of IL-6sR—
an IL-6 agonist implicated in IL-6 trans-signaling [38]. More-
over, SPARC inhibited the basal and LPA-induced production
of MCP-1, a major chemoattractant of peritoneal macro-
phages, thus suppressing another significant source of LPA
and IL-6 production in ascitic fluid. Collectively, our data
suggest that the role of SPARC as a negative regulator of
IL-6 is mainly mediated through the drastic diminution of its
production from ovarian cancer cells and other cell types in
the microenvironment of peritoneal ovarian carcinomatosis.
Further studies are warranted for the in vivo use of SPARC,
not only to block the tumor-promoting effects of IL-6 but also
to alleviate associated psychosocial disturbances and to
improve the quality of life of ovarian cancer patients.
In summary, we have provided evidence that through
interference with mesothelial cancer cell crosstalk and con-
comitant attenuation of LPA activities, SPARC is implicated
as a crucial player in the normalization of the reactive
microenvironment of peritoneal ovarian carcinomatosis. Our
finding that rescuing the expression of SPARC in ovarian
Figure 9. SPARC antagonizes IL-6– induced chemotaxis and invasion of ovarian cancer cells. The chemotactic activity of SKOV3 (A) and OVCAR3 (B) cells
toward IL-6 was tested as described previously. The indicated concentrations of IL-6 were used to attract ovarian cancer cells either alone or after pretreatment of
cells with SPARC (10 g/ml) for 2 hours. As control, the IL-6–neutralizing antibody (50 g/ml) was mixed with SFM containing IL-6 (50 ng/ml) for 30 min before use
in chemotaxis assay. *P < .05, from PBS-treated (control) cells. **P < .05, from matched control or IL-6–stimulated cells. FN invasion by SKOV3 (C) and OVCAR3
(D) cells was studied under the same conditions as described for the chemotaxis assay, with the exception that IL-6 was added to the cells in the upper chamber of
the transwell inserts and cells were allowed to migrate toward a complete growth medium. Pretreatment of either SKOV3 or OVCAR3 cells with the IL-6–
neutralizing antibody (50 g/ml) for 30 minutes was used as control. *P < .05, from control PBS-treated cells. **P < .05, from matched control or IL-6–stimulated
cells. Results are expressed as the mean ± SEM of the number of cells per field that migrated to and/or invaded the lower surface of the inserts. Experiments were
performed in triplicate per experimental condition and were repeated thrice with similar results.
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cancer cells through gene transfer antagonized the tumor-
promoting properties of LPA and its downstream effector
IL-6, combined with its established antiproliferative, pro-
apoptotic, and antimetastatic properties, highlights its thera-
peutic potential as a promising novel inhibitor of peritoneal
ovarian carcinomatosis.
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